Latest Annexin Pharmaceuticals News & Updates

See the latest news and media coverage for Annexin. We track all announcements, press releases, and industry mentions in real time, all in one place.

Annexin Pharmaceuticals (Annexin)

Clinical-stage biotechnology company developing Annexin A5 therapeutics

annexinpharma.com

Headquarters: Stockholm, Sweden
Founded year: 2014
Company type: Public company
Number of employees: 8–10
Industry: Biotechnology & Medical Research

Last updated September 16

Latest news about Annexin Pharmaceuticals (Annexin)

In short: Annexin completed NEXUS enrollment and expanded trial to anti-VEGF combination

Company announcements

July 3 Annexin

Annexin's rights issue was 98 percent subscribed

The subscription period ended on 2 July 2026, and the company will receive 19.9 MSEK before costs.

June 23 Annexin

Annexin Pharmaceuticals reports positive data from NEXUS study in DR and RVO

Treatment with ANXV showed improved retinal perfusion and was well tolerated, supporting further development.

June 3 Annexin

Annexin resolves a SEK 20 million rights issue, 60% secured

The issue includes an overallotment option of up to SEK 5 million to fund phase 2a study NEXUS.

April 22 Annexin

Annexin accelerates patient recruitment in NEXUS study

Five patients treated for RVO and DR with no safety issues. Promising initial results observed. Recruitment continues.

Media coverage

September 16 BioStock

First patient treated with anti-VEGF and vanexin in Annexin's NEXUS study - Biostock

In August, Annexin announced that the NEXUS study would be expanded to include, alongside monotherapy with vanexin, patients with retinal vein occlusion (RVO) who had...

August 21 Finanzen.ch

Annexin Pharmaceuticals Registered reported figures for the most recent quarter

Annexin Pharmaceuticals Registered presented the balance sheet figures for the year quarter ending on June 30, 2026, on August 21, 2026. Regarding EPS, a...

July 3 AffärsVärlden

Annexin: Almost fully subscribed despite meager discount

Annexin Pharmaceuticals' rights issue of shares was subscribed to 97.9% and the company thus receives SEK 19.9 million before expenses. Emissionsguiden raises a flag.

June 23 Finanznachrichten

Annexin Pharmaceuticals AB: Annexin updates on continuous promising data from the NEXUS study - demonstrating improvement of retinal perfusion in both DR and RVO

Annexin Pharmaceuticals AB announces an update on the NEXUS study key preliminary clinical findings. To date, treatment with the drug candidate ANXV has not been...

Never miss news about Annexin

Track Annexin and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Annexin competitors & trending companies

Browse news for competitors to Annexin and other trending companies.